Welcome to our dedicated page for Zai Lab news (Ticker: ZLAB), a resource for investors and traders seeking the latest updates and insights on Zai Lab stock.
Zai Lab Limited (ZLAB) is a research-based, commercial-stage biopharmaceutical company based in China and the United States, with a focus on oncology, immunology, neuroscience, and infectious disease. The Zai Lab news feed on Stock Titan aggregates company announcements, clinical updates, regulatory milestones, and financial disclosures that the company releases through channels such as Business Wire and SEC filings.
Investors and followers of ZLAB stock can use this page to review news on Zai Lab’s global pipeline, including progress of assets like zocilurtatug pelitecan (zoci), a DLL3-targeted antibody-drug conjugate for extensive-stage small cell lung cancer and other neuroendocrine carcinomas, and ZL-1503, an IL-13/IL-31R bispecific antibody for atopic dermatitis. Updates on other oncology and immunology programs, such as ZL-6201, ZL-1222, and ZL-1311, also appear in company press releases.
The news stream highlights regulatory developments in Greater China, including National Medical Products Administration (NMPA) approvals and National Reimbursement Drug List (NRDL) decisions for products in Zai Lab’s commercial portfolio. Recent examples include announcements about COBENFY for schizophrenia and AUGTYRO for ROS1-positive non-small cell lung cancer and NTRK-positive solid tumors, as well as renewals and coverage decisions for VYVGART, NUZYRA, and ZEJULA.
In addition, this page surfaces Zai Lab’s financial result releases, conference call notices, and participation in healthcare and investor conferences. These items provide context on revenue trends, R&D spending, and the company’s dual-engine strategy combining a China commercial business with a global innovation platform. Bookmark this page to quickly access ZLAB-related news, organized in one place for efficient review of the company’s ongoing clinical, regulatory, and corporate developments.
Zai Lab Limited (NASDAQ: ZLAB) announced that its drugs QINLOCK® (ripretinib) and NUZYRA® (omadacycline) have been added to China's National Reimbursement Drug List (NRDL). This inclusion is significant for patients with advanced gastrointestinal stromal tumors and community-acquired bacterial pneumonia. William Liang, Zai Lab's Chief Commercial Officer, emphasized that NHSA reimbursement will expand patient access to these treatments. Both drugs previously received regulatory approval in China, with NUZYRA launched in 2019. GIST affects approximately 30,000 new patients annually in China, highlighting a critical need for effective treatments.
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) announced the appointment of Michel Vounatsos to its Board of Directors, effective January 7, 2023. Vounatsos has over 25 years of experience in the biopharmaceutical sector, including leadership roles at Biogen and Merck. His extensive commercial background, particularly in neuroscience and operations in China, is expected to enhance Zai Lab's growth and product commercialization efforts. The company currently has four drugs on the market and plans to launch three more, aiming to improve patient care in China and globally.
The LUNAR study by Zai Lab and Novocure has achieved its primary endpoint, showing a statistically significant improvement in overall survival for stage 4 non-small cell lung cancer (NSCLC) patients.
The study demonstrated enhanced survival rates for patients receiving Tumor Treating Fields (TTFields) alongside standard treatments compared to those receiving standard treatments alone. Notably, results indicated a positive trend in survival with TTFields combined with docetaxel. Novocure plans to present the complete findings at an upcoming medical conference and file for FDA approval in late 2023.
Zai Lab Limited (NASDAQ: ZLAB) announced the appointment of Dr. Rafael G. Amado as President and Head of Global Oncology Research and Development, effective December 30, 2022. Dr. Amado, with extensive oncology expertise, previously held leadership roles at Allogene Therapeutics and Adaptimmune. His appointment aims to enhance Zai Lab's oncology R&D capabilities, supporting the company's goal of becoming a leading global biopharmaceutical entity. Dr. Amado's focus will be on accelerating existing and future oncology programs to address unmet medical needs in China and globally.
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) announced its participation in key investor conferences in January 2023. The company will be present at the Morgan Stanley Virtual China Opportunity Conference from January 4-6, and will present at the J.P. Morgan 41st Annual Healthcare Conference on January 10 at 9:00 a.m. PST in San Francisco. The webcast for the J.P. Morgan conference will be accessible on Zai Lab’s Investor Relations site, with an archived replay available for 30 days. Zai Lab focuses on developing transformative medicines in oncology, autoimmune disorders, infectious diseases, and neurological disorders.
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) presented new interim overall survival (OS) data for ZEJULA® (niraparib) in patients with platinum-sensitive recurrent ovarian cancer at the ESMO Virtual Plenary. The median overall survival was 46.3 months for ZEJULA compared to 43.4 months for placebo. Notably, the results suggest a favorable trend in OS regardless of gBRCA mutation status. No new safety concerns were identified in the study. The final OS analysis is anticipated in 2023, further establishing ZEJULA's role as a second-line maintenance therapy for ovarian cancer.
Zai Lab announced promising preliminary results for adagrasib combined with pembrolizumab in treating first-line advanced/metastatic NSCLC with KRASG12C mutation. Data from the KRYSTAL-7 Phase 2 trial and KRYSTAL-1 Phase 1b cohort show favorable tolerability and an overall response rate (ORR) of 49%, with a notable 56% in a select subset. The safety profile revealed manageable treatment-related adverse events. This data will be presented on December 7 at the ESMO Immuno-Oncology Congress, highlighting the potential of this combination therapy for treatment-naïve patients.
Zai Lab reported third-quarter 2022 revenues of $57.5 million, marking a 33% year-on-year and 19% quarter-on-quarter increase. This growth is driven by the success of ZEJULA and a new collaboration for TIVDAK. The company maintains a strong balance sheet with $1.12 billion in cash, supporting operations through 2025. R&D expenses rose to $99.5 million, influenced by increased clinical trial costs and a $30 million upfront payment to Seagen. Despite these expenses, Zai Lab expects net product revenue to surpass costs in 2023.
Zai Lab Limited (NASDAQ: ZLAB) will present new data on its immuno-oncology pipeline at the upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting from November 8-12, 2022, in Boston, Mass. The focus will be on two key programs: ZL-1211 (anti-CLDN18.2 antibody) for gastric cancer and ZL-1218 (anti-CCR8 antibody) for solid tumors. Presentations will feature research on enhancing anti-tumor activities and targeting intratumoral Treg subpopulations, showcasing Zai Lab's commitment to advancing its global R&D pipeline.
Zai Lab Limited (NASDAQ: ZLAB) has appointed Dr. Peter Huang as its new Chief Scientific Officer, effective immediately. Dr. Huang, with over 16 years in the biopharmaceutical sector, previously held senior roles at Zentalis Pharmaceuticals and Pfizer. He will lead Zai Lab's discovery efforts and translational medicine, aiming to advance the company’s innovative drug pipeline. Dr. Huang expressed enthusiasm about overseeing product development that addresses unmet medical needs both in China and globally.